Pharmacological and Non-pharmacological Treatments for Irritable Bowel Syndrome: Protocol for a Systematic Review and Network Meta-analysis

Overview

Journal Medicine (Baltimore)

Specialty General Medicine

Date 2019 Jul 27

PMID 31348246

Citations 3

Authors

Shenghui Zhou

Xiaoli Liu

Xiaoxia Wang

Fenglin Xi

Xiaoke Luo

Liang Yao

Hao Tang

Affiliations

Soon will be listed here.

Abstract

Background: The global prevalence of Irritable bowel syndrome (IBS) is estimated to be as high as 15% and a number of different non-pharmacological and pharmacological treatments have been used to manage IBS in clinical practice, which poses great challenges for clinicians to make appropriate decisions. Hence, a systematic review and network meta-analysis on all available pharmacological and non-pharmacological treatments for IBS is needed to provide reliable evidence.

Methods: We will search the Cochrane Central Register of Controlled Trials (CENTRAL), the Cochrane IBD Group Specialized Trials Register, MEDLINE, EMBASE, and Chinese Biomedical medicine (CBM) from inception to 31, May 2019. Randomized controlled trials of pharmacological and nonpharmacological interventions for IBS will be included. Study quality will be assessed on the basis of the methodology and categories described in the Cochrane Collaboration Handbook. Primary outcomes are global or clinical improvement and quality of life. A Bayesian network meta-analysis would be performed, and relative ranking of agents would be assessed. A node splitting method will be used to examine the inconsistency between direct and indirect comparisons when a loop connecting 3 arms exists.

Results: Researchers will rank the effectiveness and safety of the potentials interventions for IBS according the characteristics of patients by conducting an advanced network meta-analysis based on Bayesian statistical model, and interpret the results by using GRADE approach.

Conclusion: The conclusion of our study will provide updated evidence to rank the effectiveness and safety of pharmacological and non-pharmacological interventions for IBS.

Ethics And Dissemination: Ethical approval is not applicable since this study is a network meta-analysis based on published trials.

Protocol Registration Number: CRD42018083844.

Citing Articles

Effects of Physical Exercise on the Microbiota in Irritable Bowel Syndrome.

Li C, Li J, Zhou Q, Wang C, Hu J, Liu C Nutrients. 2024; 16(16).

PMID: 39203794 PMC: 11356817. DOI: 10.3390/nu16162657.

Performance and Interpretation of Hydrogen and Methane Breath Testing Impact of North American Consensus Guidelines.

Pitcher C, Farmer A, Haworth J, Treadway S, Hobson A Dig Dis Sci. 2022; 67(12):5571-5579.

PMID: 35366119 PMC: 9652228. DOI: 10.1007/s10620-022-07487-8.

Adherence and Effects Derived from FODMAP Diet on Irritable Bowel Syndrome: A Real Life Evaluation of a Large Follow-Up Observation.

Gravina A, Dallio M, Romeo M, Di Somma A, Cotticelli G, Loguercio C Nutrients. 2020; 12(4).

PMID: 32230832 PMC: 7231245. DOI: 10.3390/nu12040928.

References

Hoaglin D, Hawkins N, Jansen J, Scott D, Itzler R, Cappelleri J . Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 2. Value Health. 2011; 14(4):429-37. DOI: 10.1016/j.jval.2011.01.011. View

Kwan A, Hu W, Chan Y, Yeung Y, Lai T, Yuen H . Prevalence of irritable bowel syndrome in Hong Kong. J Gastroenterol Hepatol. 2002; 17(11):1180-6. DOI: 10.1046/j.1440-1746.2002.02871.x. View

Quigley E, Fried M, Gwee K, Khalif I, Hungin A, Lindberg G . World Gastroenterology Organisation Global Guidelines Irritable Bowel Syndrome: A Global Perspective Update September 2015. J Clin Gastroenterol. 2016; 50(9):704-13. DOI: 10.1097/MCG.0000000000000653. View

Thompson C . Novartis suspends tegaserod sales at FDA's request. Am J Health Syst Pharm. 2007; 64(10):1020. DOI: 10.2146/news070044. View

Begg C, Mazumdar M . Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994; 50(4):1088-101. View

Jackson J, OMalley P, TOMKINS G, Balden E, Santoro J, Kroenke K . Treatment of functional gastrointestinal disorders with antidepressant medications: a meta-analysis. Am J Med. 2000; 108(1):65-72. DOI: 10.1016/s0002-9343(99)00299-5. View

Liu J, Yang M, Liu Y, Wei M, Grimsgaard S . Herbal medicines for treatment of irritable bowel syndrome. Cochrane Database Syst Rev. 2006; (1):CD004116. DOI: 10.1002/14651858.CD004116.pub2. View

Sweetser S, Busciglio I, Camilleri M, Bharucha A, Szarka L, Papathanasopoulos A . Effect of a chloride channel activator, lubiprostone, on colonic sensory and motor functions in healthy subjects. Am J Physiol Gastrointest Liver Physiol. 2008; 296(2):G295-301. PMC: 2643920. DOI: 10.1152/ajpgi.90558.2008. View

Callahan M . Irritable bowel syndrome neuropharmacology. A review of approved and investigational compounds. J Clin Gastroenterol. 2002; 35(1 Suppl):S58-67. DOI: 10.1097/00004836-200207001-00011. View

10.

Ikechi R, Fischer B, DeSipio J, Phadtare S . Irritable Bowel Syndrome: Clinical Manifestations, Dietary Influences, and Management. Healthcare (Basel). 2017; 5(2). PMC: 5492024. DOI: 10.3390/healthcare5020021. View

11.

Milne R, Heel R . Ondansetron. Therapeutic use as an antiemetic. Drugs. 1991; 41(4):574-95. DOI: 10.2165/00003495-199141040-00006. View

12.

Halpert A, Dalton C, Diamant N, Toner B, Hu Y, Morris C . Clinical response to tricyclic antidepressants in functional bowel disorders is not related to dosage. Am J Gastroenterol. 2005; 100(3):664-71. DOI: 10.1111/j.1572-0241.2005.30375.x. View

13.

McFarland L, Dublin S . Meta-analysis of probiotics for the treatment of irritable bowel syndrome. World J Gastroenterol. 2008; 14(17):2650-61. PMC: 2709042. DOI: 10.3748/wjg.14.2650. View

14.

Austin G, Dalton C, Hu Y, Morris C, Hankins J, Weinland S . A very low-carbohydrate diet improves symptoms and quality of life in diarrhea-predominant irritable bowel syndrome. Clin Gastroenterol Hepatol. 2009; 7(6):706-708.e1. PMC: 2693479. DOI: 10.1016/j.cgh.2009.02.023. View

15.

Goldberg P, Kamm M, van der Sijp J, Roth C . Modification of visceral sensitivity and pain in irritable bowel syndrome by 5-HT3 antagonism (ondansetron). Digestion. 1996; 57(6):478-83. DOI: 10.1159/000201377. View

16.

Lang L . The Food and Drug Administration approves lubiprostone for irritable bowel syndrome with constipation. Gastroenterology. 2008; 135(1):7. DOI: 10.1053/j.gastro.2008.06.004. View

17.

Oswiecimska J, Szymlak A, Roczniak W, Girczys-Poledniok K, Kwiecien J . New insights into the pathogenesis and treatment of irritable bowel syndrome. Adv Med Sci. 2017; 62(1):17-30. DOI: 10.1016/j.advms.2016.11.001. View

18.

Peters J, Sutton A, Jones D, Abrams K, Rushton L . Contour-enhanced meta-analysis funnel plots help distinguish publication bias from other causes of asymmetry. J Clin Epidemiol. 2008; 61(10):991-6. DOI: 10.1016/j.jclinepi.2007.11.010. View

19.

Wu H, Huang J, Lin H, Liao W, Peng Y, Hung K . Comparative effectiveness of renin-angiotensin system blockers and other antihypertensive drugs in patients with diabetes: systematic review and bayesian network meta-analysis. BMJ. 2013; 347:f6008. PMC: 3807847. DOI: 10.1136/bmj.f6008. View

20.

Hanauer S . The benefits of loperamide in the treatment of patients with IBS or IBD. Introduction. Rev Gastroenterol Disord. 2008; 7 Suppl 3:S1-2. View